Insulin icodec / Semaglutide
依柯胰岛素司美格鲁肽Fixed-ratio once-weekly basal insulin and GLP-1 agonist combination (IcoSema) newly added to the 2026 NRDL Negotiated List (#18) for adult T2D.
China Approval (NMPA)
Approved- Approval Number(s)
- 国药准字SJ20260018
- Initial Approval Date
- Oct 15, 2026
- Notice Published
- Oct 15, 2026
- MAH
- Novo Nordisk A/S (诺和诺德)
- Approved Scope
- Expanded to adults with Type 2 Diabetes inadequately controlled on oral antidiabetic drugs (OADs); initial March 2026 approval covered patients uncontrolled on basal insulin or GLP-1 RAs.
National Reimbursement
Announced · Effective Jan 1, 2027- 2026 Edition Entry
- Negotiated #18 · Class B
- Agreement Period
- 2027-01-01 to 2028-12-31
- Payment Standard
- * Confidential (marked with asterisk in NHSA PDF)
- 2026 Payment Scope
- Restricted to adults with Type 2 Diabetes mellitus inadequately controlled on basal insulin or a GLP-1 receptor agonist.
- 限接受基础胰岛素或胰高糖素样肽1(GLP-1)受体激动剂治疗后血糖控制不佳的成人2型糖尿病患者。
Commercial Insurance List
Not ListedNot listed in the 2025 or 2026 NHSA Commercial Health Insurance Innovative Drug List.
Approved Products, Dosage Forms & Approval Numbers
1 verified NMPA record| Approval No. | Dosage Form & Strength | Event & Scope | Approval / Notice Date | MAH & Source |
|---|---|---|---|---|
| 国药准字SJ20260018 | Injection (注射液) Pre-filled pen (SJ20260018 / SJ20260019 / SJ20260020) | Supplemental Indication Expanded to adults with Type 2 Diabetes inadequately controlled on oral antidiabetic drugs (OADs); initial March 2026 approval covered patients uncontrolled on basal insulin or GLP-1 RAs. 新增适用于接受口服降糖药(OADs)治疗血糖控制不佳的成人2型糖尿病患者(首发适应症于2026年3月获批用于基础胰岛素或GLP-1RA控制不佳患者)。 | Approved: 2026-10-15 Published: 2026-10-15 | Novo Nordisk A/S |
Change Timeline
- (2027-01-01)Basic NRDL· Catalog published: Nov 14, 2026
2026 NRDL · Added to Negotiated List
Newly added to 2026 NRDL Negotiated List (#18, Class B, *) for adult T2D inadequately controlled on basal insulin or GLP-1 receptor agonist.
Chinese original: 新增纳入2026版谈判药品第18项(乙类,支付标准*),限基础胰岛素或GLP-1受体激动剂控制不佳的成人2型糖尿病患者。
NHSA · PDF p.118Verified 2026-11-20 - (2026-10-15)NMPA Approval
NMPA Supplemental Indication Approval (国药准字SJ20260018 · Pre-filled pen (SJ20260018 / SJ20260019 / SJ20260020))
Expanded to adults with Type 2 Diabetes inadequately controlled on oral antidiabetic drugs (OADs); initial March 2026 approval covered patients uncontrolled on basal insulin or GLP-1 RAs.
Chinese original: 新增适用于接受口服降糖药(OADs)治疗血糖控制不佳的成人2型糖尿病患者(首发适应症于2026年3月获批用于基础胰岛素或GLP-1RA控制不佳患者)。
NMPA · NMPA Approval Record SJ20260018Verified 2026-11-21
Verified Names & Aliases
Every English INN, Chinese generic name, brand name, and R&D code is recorded with its source.
Primary Sources for This Record
- NHSAPublished 2026-11-14国家基本医疗保险、生育保险和工伤保险药品目录(2026年)Retrieved 2026-11-20
- NMPA国家药监局药品监管动态Retrieved 2026-11-20
- WHO世界卫生组织国际非专利药名(INN)指南Retrieved 2026-11-20